Proteoglycans in the control of tumor growth and metastasis formation

Connective Tissue Research

Volumn 49, Issue 3-4, 2008, Pages 225-229

  Cattaruzza, Sabrina ^a,b   Nicolosi, Pier Andrea ^a,b   Perris, Roberto ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Metastasis; NG2; Proteoglycans; Tumor

Indexed keywords

AGGRECAN; ANTINEOPLASTIC AGENT; BIGLYCAN; DECORIN; FIBROMODULIN; GLYPICAN; GLYPICAN 1; GLYPICAN 2; GLYPICAN 3; GROWTH FACTOR; HERMES ANTIGEN; KERATOCAN; LIGAND; LUMICAN; MONOCLONAL ANTIBODY 9.2.27 BI 217; PERLECAN; PROTEIN ANTIBODY; PROTEIN NG2; PROTEOGLYCAN; SYNDECAN 1; SYNDECAN 2; VERSICAN;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CHORDOMA; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR GROWTH;

ANIMALS; ANTIGENS; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; PROTEOGLYCANS; SIGNAL TRANSDUCTION;

EID: 48549094284     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.1080/03008200802143448     Document Type: Article

References (28)

1. Joseph, R., Bishop, J. R., Schuksz, M. and Esko, J. D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. 446
2. Cattaruzza, S. and Perris, R. (2006) Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. 6, pp. 667-680.
3. Oh, E. S. and Couchman, J. R. (2004) Syndecans-2 and -4: Close cousins, but not identical twins. 17, pp. 181-187.
4. Simons, M. and Horowitz, A. (2001) Syndecan-4-mediated signalling. 13, pp. 855-862.
5. Tkachenko, E., Rhodes, J. M. and Simons, M. (2004) Syndecans new kids on signaling block. 96, pp. 488-500.
6. Zhang, Y., Li, J., Partovian, C., Sellke, F. W. and Simons, M. (2003) Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. 284, pp. 2078-2082.
7. Fjeldstad, K. and Kolset, S. O. (2005) Decreasing the metastatic potential in cancers: Targeting the heparan sulfate proteoglycans. 6, pp. 665-682.
8. Ricciardelli, C., Mayne, K., Sykes, P. J., Raymond, W. A., McCaul, K., Marshall, V. R., Tilley, W. D., Skinner, J. M. and Horsfall, D. J. (1997) Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. 6, pp. 983-992.
9. Leygue, E., Snell, L., Dotzlaw, H., Troup, S., Hiller-Hitchcock, T., Murphy, L. C., Roughley, P. J. and Watson, P. H. (2000) Lumican and decorin are differentially expressed in human breast carcinoma. 192, pp. 313-320.
10. Nara, Y., Kato, Y., Torii, Y., Tsuji, Y., Nakagaki, S., Goto, S., Isobe, H., Nakashima, N. and Takeuchi, J. (1997) Immunohistochemical localization of extracellular matrix components in human breast tumors with special reference to PG-M/versican. 1, pp. 21-30.
11. Labropoulou, V. T., Theocharis, A. D., Ravazoula, P., Perimenis, P., Hjerpe, A., Karamanos, N. K. and Kalofonos, H. P. (2006) Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumors. 49, pp. 582-593.
12. Kodama, J., Hasengaowa, Kusumoto, T., Seki, N., Matsuo, T., Ojima, Y., Nakamura, K., Hongo, A. and Hiramatsu, Y. (2007) Prognostic significance of stromal versican expression in human endometrial cancer. 18, pp. 269-274.
13. Miquel-Serra, L., Serra, M., Hernandez, D., Domenzain, C., Docampo, M. J., Rabanal, R. M., de Torres, I., Wight, T. N., Fabra, A. and Bassols, A. (2006) V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. 86, pp. 889-901.
14. Yee, A. J., Akens, M., Yang, B. L., Finkelstein, J., Zheng, P. S., Deng, Z. and Yang, B. (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. 9, p. R47.
15. Ladanyi, A., Gallai, M., Paku, S., Nagy, J. O., Dudas, J., Timar, J. and Kovalszky, I. (2001) Expression of a decorin-like moleculein human melanoma. 7, pp. 260-266.
16. Blackhall, F. H., Merry, C. L., Davies, E. J. and Jayson, G. C. (2001) Heparan sulfate proteoglycans and cancer. 19, pp. 1094-1098.
17. Sanderson, R. D. (2001) Heparan sulfate proteoglycans in invasion and metastasis. 12, pp. 89-98.
18. Yang, Y., Macleod, V., Miao, H. Q., Theus, A., Zhan, F., Shaughnessy Jr, J. D., Sawyer, J., Li, J. P., Zcharia, E., Vlodavsky, I. and Sanderson, R. D. (2007) Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis. 282, pp. 13326-13333.
19. Stallcup, W. B. (2002) The NG2 proteoglycan: Past insights and future prospects. 31, pp. 423-435.
20. Lynch, S. A., Bouchard, B. N., Vijayasaradhi, S., Yuasa, H. and Houghton, A. N. (1991) Antigens of melanocytes and melanoma. 10, pp. 141-150.
21. Burg, M. A., Grako, K. A. and Stallcup, W. B. (1998) Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. 177, pp. 299-312.
22. Lin, X. H., Dahlin-Huppe, K. and Stallcup, W. B. (1996) Interaction of the NG2 proteoglycan with the actin cytoskeleton. 63, pp. 463-477.
23. Fang, X., Burg, M. A., Barritt, D., Dahlin-Huppe, K., Nishiyama, A. and Stallcup, W. B. (1999) Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. 10, pp. 3373-3387.
24. Barritt, D. S., Pearn, M. T., Zisch, A. H., Lee, S. S., Javier, R. T., Pasquale, E. B. and Stallcup, W. B. (2000) The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. 79, pp. 213-224.
25. Allen, B. J., Rizvi, S., Li, Y., Tian, Z. and Ranson, M. (2001) In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. 39, pp. 139-146.
26. Allen, B. J., Rizvi, S. M. A. and Tian, Z. (2001) Preclinical targeted alpha therapy for subcutaneous melanoma. 11, pp. 175-182.
27. 213Bi-9.2.27 α-immunoconjugate induces cytotoxicity in human uveal melanoma cells. 46, pp. 4365-4371.
28. Bumol, T. F., Wang, Q. C., Reisfeld, R. A. and Kaplan, N. O. (1983) Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. 80, pp. 529-533.